Molecular characterization of treatment-naïve esophageal adenocarcinoma with NanoString GeoMx® proteome digital spatial profiling

Join us for this webinar, co-sponsored between NanoString and Illumina as we discuss how to leverage the power of Spatial Biology to advance the frontiers of cancer research.

Giuseppina Arbore PhD, from DIBIT San Raffaele Scientific Institute, Italy presents: Esophageal adenocarcinoma (EAC) is a highly aggressive malignancy, and less than 30% of patients treated with neoadjuvant chemotherapy (nCT) achieve a pathological complete response associated with increased 5-year overall survival. We investigated the immune mechanisms underlying the response to nCT in esophageal adenocarcinoma by multi-dimensional profiling of treatment-naïve tumor biopsies and blood, integrated with tumor molecular and immune profiling with the Nanostring technologies GeoMx® proteome digital spatial profiling (DSP). Collectively our results suggest that pre-existing immunity in baseline tumors drives the clinical activity of nCT in locally advanced EAC and that it may be possible to stratify patients based on predictive immune signatures, enabling tailored neoadjuvant and/or adjuvant regimens.

In partnership with: